Trial Number
790-17
Condition
Prostate Cancer
Participant Age Range
21 Years and older
Participant Gender
Male
Enrolling Participants
Yes
Overview
“Prospective Evaluation of TrueBeam / Edge Stereotactic Body Radiotherapy for Localized Prostate Cancer: Risk Stratified Monotherapy versus Radiosurgery Boost”
The primary safety purpose of this study is to estimate the rates of immediate and long-term high grade (grade 3-5) gastrointestinal and genitourinary side effects during the five years after TrueBeam stereotactic body radiotherapy in low-risk and intermediate-risk prostate cancer patients. The primary efficacy purpose is to compare 5 year biochemical disease free survival rates with TrueBeam to 5 year biochemical diseases free survival rates with dose-escalated external beam radiation therapy.